KRAS and non-small cell lung carcinoma: To demonstrate that our findings in vitro are relevant in the clinical setting, we examined tumors from four ROS1+ NSCLC patients who relapsed upon crizotinib treatment for the presence of KRAS/NRAS mutations and KRAS amplification.